Enalapril
- Generic Name
- Enalapril
- Brand Names
- Epaned, Vaseretic, Vasotec, Aqumeldi
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28N2O5
- CAS Number
- 75847-73-3
- Unique Ingredient Identifier
- 69PN84IO1A
- Background
Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypertensive agent that suppresses the renin-a...
- Indication
Indicated for the management of essential or renovascular hypertension as monotherapy or in combination with other antihypertensive agents, such as thiazide diuretics, for an additive effect.
Indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis.
...
- Associated Conditions
- Diabetic Nephropathy, Hypertension, Symptomatic Congestive Heart Failure, Asymptomatic Left ventricular dysfunction
- Associated Therapies
- -
Renin Angiotensin System Study (RASS/B-RASS)
- Conditions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2008-11-06
- Lead Sponsor
- Michael Mauer, MD
- Target Recruit Count
- 285
- Registration Number
- NCT00143949
- Locations
- 🇨🇦
Mt Sinai Hospital, University of Toronto (Clinical Ctr), Toronto, Ontario, Canada
🇨🇦Montreal Childrens Hospital, McGill University (Clinical Ctr), Montreal, Quebec, Canada
🇨🇦Royal Victoria Hospital, McGill University (Data Center), Montreal, Quebec, Canada
Angiotensin Converting Enzyme Inhibition in Children With Mitral Regurgitation
- Conditions
- Interventions
- First Posted Date
- 2005-06-10
- Last Posted Date
- 2014-03-13
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 5
- Registration Number
- NCT00113698
- Locations
- 🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Trial of Angiotensin Converting Enzyme Inhibition in Infants With Single Ventricle--Pediatric Heart Network
- Conditions
- Interventions
- First Posted Date
- 2005-06-06
- Last Posted Date
- 2010-09-28
- Target Recruit Count
- 230
- Registration Number
- NCT00113087
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-03-01
- Last Posted Date
- 2014-08-05
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 13
- Registration Number
- NCT00003070
- Locations
- 🇺🇸
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇨🇦Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Pilot Study of Enalapril and Renal Function in Patients With IgA Nephropathy
- Conditions
- First Posted Date
- 2000-08-04
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 43
- Registration Number
- NCT00006137
Treatment of Mild Hypertension Study (TOMHS)
- Conditions
- First Posted Date
- 1999-10-28
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- University of Minnesota
- Registration Number
- NCT00000522
Studies of Left Ventricular Dysfunction (SOLVD)
- Conditions
Enalapril After Anthracycline Cardiotoxicity
- Conditions
Phase II Study of the Pathophysiology and Treatment With Enalapril and Polystyrene Sulfonate for Pseudohypoaldosteronism, Type I
- Conditions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 1
- Registration Number
- NCT00004328
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.